Joel Beatty

Stock Analyst at Baird

(4.58)
# 235
Out of 5,161 analysts
211
Total ratings
50.9%
Success rate
34.8%
Average return

Stocks Rated by Joel Beatty

Dianthus Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $67$132
Current: $80.32
Upside: +64.34%
Contineum Therapeutics
Mar 6, 2026
Maintains: Outperform
Price Target: $14$20
Current: $13.86
Upside: +44.30%
Praxis Precision Medicines
Feb 20, 2026
Maintains: Outperform
Price Target: $275$433
Current: $303.37
Upside: +42.73%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $72$47
Current: $21.71
Upside: +116.49%
Jazz Pharmaceuticals
Nov 18, 2025
Maintains: Outperform
Price Target: $160$209
Current: $180.32
Upside: +15.91%
e.l.f. Beauty
Nov 6, 2025
Maintains: Outperform
Price Target: $145$125
Current: $72.58
Upside: +72.22%
Amylyx Pharmaceuticals
Oct 16, 2025
Maintains: Outperform
Price Target: $10$19
Current: $14.38
Upside: +32.13%
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10$7
Current: $4.77
Upside: +46.75%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4$6
Current: $2.54
Upside: +136.22%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7$9
Current: $35.33
Upside: -74.53%
Maintains: Outperform
Price Target: $28$31
Current: $21.27
Upside: +45.75%
Downgrades: Neutral
Price Target: $38$24
Current: $22.30
Upside: +7.62%
Upgrades: Outperform
Price Target: $680
Current: $708.85
Upside: -4.07%
Maintains: Outperform
Price Target: $30$29
Current: $20.70
Upside: +40.10%
Maintains: Outperform
Price Target: $70$66
Current: $63.36
Upside: +4.17%
Maintains: Outperform
Price Target: $160$162
Current: $154.12
Upside: +5.11%
Maintains: Outperform
Price Target: $38$41
Current: $27.64
Upside: +48.34%
Maintains: Outperform
Price Target: $28$32
Current: $23.39
Upside: +36.81%
Initiates: Outperform
Price Target: $75
Current: $72.25
Upside: +3.81%
Maintains: Outperform
Price Target: $6$7
Current: $2.76
Upside: +153.62%
Maintains: Neutral
Price Target: $72$65
Current: $59.07
Upside: +10.04%
Maintains: Outperform
Price Target: $540$240
Current: $0.33
Upside: +72,495.28%
Downgrades: Neutral
Price Target: $4.5
Current: $1.60
Upside: +181.25%
Maintains: Outperform
Price Target: $24$25
Current: $15.61
Upside: +60.15%
Maintains: Outperform
Price Target: $32$28
Current: $23.99
Upside: +16.72%
Initiates: Outperform
Price Target: $16
Current: $1.33
Upside: +1,103.01%
Maintains: Outperform
Price Target: $4$1.25
Current: $1.63
Upside: -23.31%
Initiates: Outperform
Price Target: $44
Current: $1.41
Upside: +3,020.57%
Maintains: Outperform
Price Target: $60$58
Current: $55.01
Upside: +5.44%
Maintains: Outperform
Price Target: $18$24
Current: $32.83
Upside: -26.90%
Downgrades: Underperform
Price Target: $18
Current: $7.00
Upside: +157.14%
Maintains: Outperform
Price Target: $9$6
Current: $1.91
Upside: +214.14%
Upgrades: Neutral
Price Target: $36$28
Current: $9.48
Upside: +195.36%
Downgrades: Neutral
Price Target: $170$175
Current: $317.23
Upside: -44.83%
Downgrades: Neutral
Price Target: $14
Current: $9.29
Upside: +50.70%
Downgrades: Neutral
Price Target: $108
Current: $17.04
Upside: +533.80%
Maintains: Buy
Price Target: $80$78
Current: $72.34
Upside: +7.82%
Maintains: Buy
Price Target: $140$100
Current: $20.06
Upside: +398.50%
Maintains: Buy
Price Target: $480$120
Current: $16.30
Upside: +636.20%
Maintains: Buy
Price Target: $480$450
Current: $3.88
Upside: +11,497.94%
Upgrades: Buy
Price Target: n/a
Current: $2.47
Upside: -
Maintains: Buy
Price Target: $19$15
Current: $10.30
Upside: +45.63%
Upgrades: Neutral
Price Target: $14$11
Current: $12.50
Upside: -16.00%
Maintains: Neutral
Price Target: $2,400$1,200
Current: $0.45
Upside: +264,333.67%
Maintains: Buy
Price Target: $15$19
Current: $8.84
Upside: +114.93%